Consensus Kyverna Therapeutics, Inc.

Equities

KYTX

US5019761049

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
15.41 ^USD	+1.03%		+10.05%	0.00%

05-14	Kyverna Therapeutics Q1 Loss Narrows	MT
04-25	Nasdaq's revenue beats on strong demand for fintech products	RE

Evolution of the average Target Price on Kyverna Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9291858a399a06f2ed9.0jqDq-_cJT3l_WTzJ2gAlpp0iFtnvxL3asNKqW1HOio.5n214aavT2KPkBCLaQVW_9wRvm0fj1XFIfEDz0AMY1-rUvOGh-lHD9O8XA~390b059ceb7520bfcb62d03e0e0e4030

Analyst Recommendations on Kyverna Therapeutics, Inc.

JPMorgan Initiates Kyverna Therapeutics With Overweight Rating	03-04	MT
Morgan Stanley Starts Kyverna Therapeutics With Overweight Rating	03-04	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.42 USD

Average target price

42.75 USD

Spread / Average Target

+177.24%

High Price Target

48 USD

Spread / Highest target

+211.28%

Low Price Target

39 USD

Spread / Lowest Target

+152.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kyverna Therapeutics, Inc.

Morgan Stanley
JPMorgan Chase

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar